ABL Lyon

Strategic area of application
Human Medicine

Application market
Immune, AutoIm & Inflam. diseases - Neurological diseases - Oncology

Activities
Diagnostics - CRO

Technologies
Analytical & Diagnostic services - Cell Therapy - cell biology - Biobanking - Antibodies - Protein - Peptide

Presentation of company's activity
What do all therapies under development have in common? Whether in preclinical or clinical stage, they all need robust and reliable biomarker monitoring tools to track and characterize their biological effect. ABL is a global leader in immunomonitoring, offering expert biomarker testing services to advance therapies from discovery to clinical stages. Our offer combines tens of years of clinical experience, the highest quality environment, and the largest panel of immunoassay technologies in Europe Therapeutic areas include oncology, infectious diseases, inflammatory, auto-immune, or neurodegenerative conditions. High versatility: large menu of prequalified biomarkers or innovative customized assays. Using key technologies such as single-plex ELISA, multiplex Luminex or SP-X (Quanterix) immunoassays, ultra-sensitive immunoassays on SiMoA HD-1(Quanterix)or MSD platforms, ELISpot, multi-parametric flow cytometry, other cell-based assays, ABL offers multiple fit-for-purpose bioanalytical solutions and supports dozens of clinical trials.

Key features of company
Strong scientific expertise in immunology combined with a robust experience in immunomonitoring technologies Quality-focused services: regulatory compliant, full traceability and stringent quality controls Active participation to CIMT/CVC proficiency panels (ELISpot, Multimer staining, NK cells,...).   ABL Lyon is certified for R&D tax credit (CIR).  

Recent news
January 2018: ABL scales up its capabilities and starts supporting its first Phase III studies

July 2016: Platine Pharma Services becomes ABL Lyon

July 2014 : ABL Inc. acquires majority interest in Platine Pharma Services
 
June 2013 : Platine Pharma Services and Indicia Biotechnology join forces to strengthen leadership in immune-assays
 
December 2011: Indicia Biotechnology acquires the rights to the activity Immuno'line and strengthens its offering in the evaluation of the immunogenicity of biopharmaceuticals.

Skills and know-how
Our expertise include : - Assay Development and method validation for ELISA, multiplex or ultra-sensitive immuno-assay technologies. - Flow cytometry and ELISpot assay Development and method qualification - ADA measurements & characterization, - Optimal sample preparation through our international PBMC reference lab network (PBMC, Sera, Plasma, ...) - Sourcing of clinical samples - Prototyping of Diagnostic tools in coordination with bioMérieux sister company

Presentation of company's services

Immunoassay development on different technology platforms: Quanterix, Singulex, Aushon, Luminex, MSD, ELISA Method validation Bioanalysis of clinical samples (up to phase 4 studies). Functional characterization of immune cell subsets by flow cytometry (cell proliferation, cytotoxicity, cytokine secretion) Quantification of antigen-specific cellular responses by ELISpot, flow cytometry or multiplex or ultrasensitive immunoassays Receptor saturation assay by flow cytometry Immune checkpoint inhibitors and CAR-T cells testing International PBMC network and sourcing of qualified biological samples

Presentation of company's technologies

xMAP (Luminex) : bead based multiplex immunoassays QUANTERIX Simoa HD-1: automated ultrasensitive immunoassay SP-X Quanterix sensitive and multiplex immunoassays VIDAS system for IVD assays ELISpot ELISA: colorimetric, fluorimetric & luminescent FACS CANTO II, Multiparametric flow cytometry (8 colors)